GlassScriptPhysician profile
Kalyn Seale
NPI 1790451979
$4,616.22
in general payments reported to CMS, 2019-2025
29 companies · $879 in 2025
The $879 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $1,211 · 2023: $1,265 · 2024: $1,114 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $770.35 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $709.08 | 2021-2025 | |
| Lilly USA, LLC | $647.86 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $633.05 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $318.46 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.77 | 2021-2024 | Jardiance |
| Pfizer INC. | $166.90 | 2023-2025 | |
| Amgen INC. | $142.26 | 2022-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $137.18 | 2021-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $100.83 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $93.02 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $91.79 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.96 | 2021-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $73.30 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $72.43 | 2022-2024 | Trelegy Ellipta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $47.80 | 2022-2025 | Xyosted |
| Mylan Specialty L.P. | $47.58 | 2024 | Yupelri |
| Exact Sciences Corporation | $44.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $43.35 | 2022 | |
| Esperion Therapeutics, INC. | $36.30 | 2024-2025 | Nexletol |
| Ibsa Pharma INC. | $34.02 | 2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $29.00 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.95 | 2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $17.01 | 2021 | |
| Currax Pharmaceuticals LLC | $16.89 | 2022 | |
| Amarin Pharma, INC. | $16.71 | 2023 | |
| Merck Sharp & Dohme LLC | $16.32 | 2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $12.65 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalyn Seale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.